Implementing New USP Chapters for Analytical Method Validation

Size: px
Start display at page:

Download "Implementing New USP Chapters for Analytical Method Validation"

Transcription

1 Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: Today s Agenda Handling Method Changes vs. Adjustments EU, ICH; FDA, Enforcement Practices (Recent) Recommendations from USP and EP Changing HPLC column particle size and ID Verification of Compendial methods according to USP <1226> Transferring methods: New USP proposal Interactive Exercises Copyright Ludwig Huber - LabCompliance Slide 2 1

2 Reference Material Master Plan: Transfer of Analytical Methods SOP Validation of Analytical Methods Transfer of Analytical Methods Method Changes vs. Adjustments USP Stimuli Paper: Transfer of Analytical Procedures: A Proposal for a New General Chapter (Link) References (available until April 10, 2010) Copyright Ludwig Huber - LabCompliance Slide 3 FDA CGMP Regulation - 21 CFR Part (a) (2) Laboratory records shall include a statement of each method used in the testing of the sample. The statement shall indicate the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested If the method employed is in the current revision of the United States Pharmacopoeia, or in other recognized standard references, or is detailed in an approved new drug application and the referenced method is not modified, a statement indicating the method and reference will suffice. The suitability of all testing methods used shall be verified under actual condition of use. Copyright Ludwig Huber - LabCompliance Slide 4 2

3 FDA Guidelines For Method Validation Analytical Procedures and Methods Validation (Draft) FDA - Industry Guidance Bioanalytical Method Validation Methods Validation for Abbreviated New Drug Applications Guideline for Submitting Samples and Analytical Data for Methods Validation Validation of Chromatographic Methods Copyright Ludwig Huber - LabCompliance Slide 5 Other Guidelines For Method Validation ICH - Guidance for Industry - Q2(R1) Validation of Analytical Procedures - Terminology and Methodology- United States Pharmacopeia 32, <1225> : Validation of Compendial Methods, United States Pharmacopeia 32, <1226> : Verification of Compendial Methods United States Pharmacopeia 32, <621> Recommendations for Accepted Adjustments to Validated Methods : ICH = International Conference for Harmonization Copyright Ludwig Huber - LabCompliance Slide 6 3

4 Change vs. Adjustment of Methods Receiving Laboratory can not get performance as specified by transferring Laboratory Transferring to New Technology 1. Check USP <621> and EP 5, Section for allowed variables, e.g., flow rate, col. Temperature 2. If modifications are in the allowed range, perform system suitability testing. 3. If SST pass, continue with analyses. If not make further modifications. If total modifications are in allowed ranges, go back to 2. Otherwise revalidate Copyright Ludwig Huber - LabCompliance Slide 7 USP 30 - Supplement 2 <621>: Method Variations Adjustments of operating conditions to meet system suitability requirements may be necessary The user should verify the suitability of the method under the new conditions by assessing the relevant analytical performance characteristics potentially affected by the change Copyright Ludwig Huber - LabCompliance Slide 8 4

5 Allowed Variations USP/EP HPLC Column USP EP Length ±70% ±70% Internal diameter ±25% ±25% Particle size Reduction of 50%, no increase Reduction of 50%, no increase Copyright Ludwig Huber - LabCompliance Slide 9 Allowed Variations USP/EPs HPLC USP EP Flow rate ±50% ±50% Column Temperature ±10 Deg C ±10% Max 60 C Injection volume Change allowed as long as SST criteria are met May be decreased (if LOD and repeatability ok..) Copyright Ludwig Huber - LabCompliance Slide 10 5

6 Allowed Variations USP/EP HPLC USP EP ph ±0.2 ±0.2 (+-1% for neutral substances) UV wavelength Conc. of salts in buffer No change outside No adjustment manufacturer specs permitted ±10% ±10% Copyright Ludwig Huber - LabCompliance Slide 11 Allowed Variations USP/EP HPLC Mobile Phase Composition USP EP Composition of mobile phase Minor components (<50%) ±30% or ±10% absolute whichever is smaller Minor components ±30% or ±2% absolute whichever is larger Copyright Ludwig Huber - LabCompliance Slide 12 6

7 Allowed Variations USP/EP Gas Chromatography - Column USP EP Length ±70% ±70% Internal diameter ±50% ±25% Particle size Changes allowed SST must pass -50%, no increase Film Thickness -10 to +100% -10 to +100% Copyright Ludwig Huber - LabCompliance Slide 13 Allowed Variations USP/EP Gas Chromatography USP EP Flow rate ±50% ±50% Oven. Temperature ±10% ±10% Injection volume Change allowed as May be decreased long as SST criteria (if LOD and are met repeatability ok..) Copyright Ludwig Huber - LabCompliance Slide 14 7

8 Handling Instrumental Changes (USP only, HPLC only) Going from 4.6 to 2.1 or 1.0 mm columns to save mobile phase Reducing particle size to reduce analysis time 1. Colum diameter; As of Dec 1, 2009 (USP 32-2), column diameter can be reduced as long as flow rate is also reduced (performance based approach) 2. Particle size A USP discussion paper also suggests a performance based approach, but not yet official USP Stimuli Paper: Transfer of HPLC Procedures to suitable Columns of Reduced Dimensions and Particle Sizes Copyright Ludwig Huber - LabCompliance Slide 15 Flow Diagram: Change vs. Adjustment System Suitability Test Pass? no Adjust method parameters no yes Continue with sample analysis yes Pass? Changes in permitted range? no Partial or full Revalidation yes Document Run System Suitability Test Copyright Ludwig Huber - LabCompliance Slide 16 8

9 Validation of Compendial Methods? FDA GMPs refer to USP or other standards Typically no need for validation, if the method has not been modified Suitability must be verified under conditions of actual use No further guideline from FDA and equivalent international agencies USP has developed drafts on Verification of Compendial Procedures USP <1226>: Verification of Compendial Procedures) Copyright Ludwig Huber - LabCompliance Slide 17 USP <1226> - Goal and Scope Clarify on how to verify the suitability of compendial methods Provide consistency between laboratories and regulatory agencies Present a high level view of the verification process Provide guidelines on how to apply performance characteristics while allowing free flexibility to determine which performance characteristics are most appropriate For new methods, not retroactive application to already existing methods Copyright Ludwig Huber - LabCompliance Slide 18 9

10 USP <1226> Statements Users of compendial analytical procedures are not required to validate these procedures when first used in their laboratories, But documented evidence of suitability should be established under actual conditions of use. Copyright Ludwig Huber - LabCompliance Slide 19 USP <1226> Verification Process Laboratory personal should be qualified to understand and perform the compendial methods as written Acceptance criteria for verification should be established If the verification of the compendial procedure is no successful, it may be concluded that the procedure may not be suitable for use with the article being tested It may be necessary to develop and validate an alternate procedure Copyright Ludwig Huber - LabCompliance Slide 20 10

11 USP <1226> Verification Requirements (I) Verification requirements should be based on an assessment of the complexity of both the procedure and the material to which the procedure is applied Only those characteristics that are considered to be appropriate for the verification of the particular method need to be evaluated Some of the analytical performance characteristics as listed in USP <1225> may be used Copyright Ludwig Huber - LabCompliance Slide 21 USP <1226> Verification Requirements (II) The degree and extent of the verification process will depend on the verification process will depend on The level of training and experience of the user Associated equipment or instrumentation The specific procedural steps The material to be tested Copyright Ludwig Huber - LabCompliance Slide 22 11

12 Performance Characteristics to be Considered for Testing Chromatographic method: specificity to evaluate impurity profiles of drugs from different suppliers, that are not addressed in the compendial procedure Assessment of the limit of detection for an impurities procedure Precision of an assay procedure To demonstrate suitability of the compendial method under actual use Copyright Ludwig Huber - LabCompliance Slide 23 Examples where Verification is NOT Required For common compendial test procedures that are routinely performed in a laboratory Loss on drying Residue on ignition Various wet chemical procedures, e.g., acid value Simple instrumental methods, e.g., ph measurements Unless there is an indication that the compendial procedure is not appropriate for the article under test Copyright Ludwig Huber - LabCompliance Slide 24 12

13 Recommendations for Planning and Execution 1. Develop a verification plan 2. Describe test procedure, performance characteristics and acceptance criteria 3. Define and perform critical tests using USP procedure 4. Compare tests results with acceptance criteria 5. Perform and document assessment 6. Write a statement that the compendial procedure can be used Copyright Ludwig Huber - LabCompliance Slide 25 Recommendations for HPLC Performance Testing Application 1: Quantitation of major compounds of drug substances in finished drugs or APIs Tests: precision, ii specificity, ifiit linearityit Application 2: Quantitative determination of impurities in drug substances or degradation products in finished drugs Tests: Precision, specificity, quantitation limit Application 3: Limit tests of impurities in drug substances or degradation products in finished drugs Tests: Specificity, limit of detection Tests are application and instrument specific Copyright Ludwig Huber - LabCompliance Slide 26 13

14 Recommendations for Deviations If the tests don t pass acceptance criteria, identify the source of the problem Develop corrective action plan Provide additional training Use other equipment Update verification document Repeat the tests If successful, document initial results, corrective actions and final results If not successful, develop alternative procedure Copyright Ludwig Huber - LabCompliance Slide 27 Verification of Compendial Methods - Steps Change or Develop and Validate (full/partial) Document no Define Scope Match Compendial method? yes Corrective Action? Test for suitability yes no Root Cause? no Acceptable? yes Document Copyright Ludwig Huber - LabCompliance Slide 28 14

15 Occurrence of Method Transfer Sponsor company to contract lab Analytical development to QC labs Across different sites The same lab conditions Different lab conditions Existing to new instrumentation With different specifications With different technology Supplier of material to client Transfer to new instruments with different instrument characteristics Copyright Ludwig Huber - LabCompliance Slide 29 FDA 483 There is no assurance that analytical methods transferred from other laboratories are adequate for use in that the current SOP Does not require predetermined acceptance criteria for the transfer from the technical services laboratory to the Quality control laboratory Does not provide provisions for technical transfer from an external Quality Control laboratory Solely requires a ruggedness test if a validation protocol has been established for the test procedure Ref: GMP trends Copyright Ludwig Huber - LabCompliance Slide 30 15

16 Warning Letter Failure to establish and document the accuracy and reproducibility of test methods employed. (W-186) For example, methods that were validated at one facility and transferred to xxx site are being used without a methods transfer or revalidation protocol. (W-186) Ref: Copyright Ludwig Huber - LabCompliance Slide 31 FDA Warning Letter The firm does not have sufficient data to support analytical method transfer Method transfer protocol, which was prepared to transfer the analytical testing method, did not require testing of the XX (100 mg and 400 mg), and only require testing of one lot of the 200 mg tablets The method transfer protocol and the method transfer report were not signed nor dated There was no formal analytical methods transfer facilities Ref: APV Education Course, Dr. Scheidegger Copyright Ludwig Huber - LabCompliance Slide 32 16

17 FDA Warning Letter The firm failed to perform finished product test method transfers for 34 products (W-187) The firm has failed to perform method validations, method verifications, or method transfers for any of the laboratory test methods used to test active pharmaceutical ingredients (W-187) Ref: Copyright Ludwig Huber - LabCompliance Slide 33 Definition of Method Transfer Process that qualifies a laboratory to use an analytical test procedure Process of establishing documented evidence that the analytical test procedure works in the receiving laboratory as well as it does in the transferring laboratory Ref: Margareth Marques, Ph.D., US Pharmacopeia Copyright Ludwig Huber - LabCompliance Slide 34 17

18 Why Controlled Method Transfer Expected by agencies The suitability of all testing methods used shall be verified under actual condition of use Reduces failure rate Improves the quality of the testing at the new place Problems can come up due to different equipment, different analysts and lab environment Copyright Ludwig Huber - LabCompliance Slide 35 FDA Guidance on Method Transfer We recommend that you hold a training session at which personnel from your reference laboratory demonstrate the method for representatives from the participating laboratories, to highlight or clarify practical details of the assay method. During the training session, you should also discuss all aspects of the protocol(s) to ensure everyone understands the procedures and objectives This can help you identify key points that may cause difficulties in the transfer study Ref: FDA Industry Guidance: Protocol for the Conduct of Method Transfer for Type C Medicated Feed Assay Methods Copyright Ludwig Huber - LabCompliance Slide 36 18

19 USP Stimuli Paper: Transfer of Analytical Procedures: A Proposal for a New General Information Chapter Published in Pharmacopeial Forum, Nov 2009 Provides the basis for a new USP chapter: Analytical Method Transfer Content Discussion of 4 types of analytical transfer Elements recommended for transfer of analytical procedures The importance transfer protocol The analytical procedure and report Copyright Ludwig Huber - LabCompliance Slide 37 Options for Method Transfer Comparative Testing Co-validation Complete or partial validation or revalidation Omission of formal transfer Criteria: type of method (simple, complex), experience and capabilities of receiving lab Copyright Ludwig Huber - LabCompliance Slide 38 19

20 Comparative Testing Most frequently used The same tests are carried out by both labs Should only be performed with validated methods Used with complex methods Requires pre-approved protocol 2-5 lots analyzed by both labs Well defined test procedures and acceptance criteria Results are compared with a set of pre-determined acceptance criteria Copyright Ludwig Huber - LabCompliance Slide 39 Co-validation Received lab is part of original method validation Transferring and receiving lab conduct the same validation experiments Useful for methods not (fully) validated Should challenge all USP or ICH validation parameters Include receiving lab in validation inter-laboratory tests. Ensures harmonization of method at both sites A site that performs validation studies is qualified to run the method Copyright Ludwig Huber - LabCompliance Slide 40 20

21 Method Validation on/or Revalidation Received lab repeats some or all of the validation experiment Done after initial method validation Validation parameters depend on the method e.g., Limit selectivity and limit quantitation for impurities Precision for content uniformity assays Similar process as verification of compendial methods Copyright Ludwig Huber - LabCompliance Slide 41 Transfer Waivers Method is used without special revalidation or testing Reasons should be well justified and documented Receiving lab already testing the product and is familiar with the method Receiving lab already testing a similar method Method developer moves from transferring to receiving ii lb lab Waiver should be well justified and documented Copyright Ludwig Huber - LabCompliance Slide 42 21

22 Prerequisites for Successful Method Transfer Analytical methods validated Includes ruggedness testing Includes robustness testing Scope well defined Sample, matrix Performance characteristics, acceptance criteria Equipment, Copyright Ludwig Huber - LabCompliance Slide 43 Required Documents Transfer Master Plan (TMP) used as frame work Transfer project plan or method transfer protocol (MTP) Approach for controlled transfer and justification SOPS for step-by-step implementation Templates and forms for efficiency i and consistency Copyright Ludwig Huber - LabCompliance Slide 44 22

23 Transfer Plan or MT Protocol Reason and purpose of the transfer Scope of the plan and method transfer The approach Description of transfer process Responsibilities Transferring, receiving labs, project owners, QA Assumptions E.g., Analysts in the receiving i lab not familiar with the method Training details Test Plan MTP = Method Transfer Protocol Copyright Ludwig Huber - LabCompliance Slide 45 Test Plan Tests to be performed and test parameters Rational behind tests Description of materials and samples Description of equipment Number of lots, batches replicates, injections Pitfalls that may be encountered Test schedule Acceptance criteria Documentation, approvals Copyright Ludwig Huber - LabCompliance Slide 46 23

24 Two Step Process Step 1: Analysts in receiving familiar with the method Ensures that the receiving lab understand the method and have the equipment and expertise to perform the analysis Receiving lab performs complete analysis according to the protocol Step 2 Comparative tests with the complete transfer study set Ref: FDA Industry Guidance: Protocol for the Conduct of Method Transfer for Type C Medicated Feed Assay Methods Copyright Ludwig Huber - LabCompliance Slide 47 Steps for Comparative Testing Develop and approve a test plan Order missing equipment and materials Training Concurrent execution of the protocol Evaluation of test results Compare with acceptance criteria Resolution of deviations, if there are any Gather all required documents Write method transfer report (MTR) Copyright Ludwig Huber - LabCompliance Slide 48 24

25 Experiments - Example Five replicates of the study samples Five replicates of the study samples fortified at 0.5x the lowest expected concentration Five replicates of the study samples fortified at 1.5x the highest expected concentration Analyze the study sample set over several days Ref: FDA Industry Guidance: Protocol for the Conduct of Method Transfer for Type C Medicated Feed Assay Methods Copyright Ludwig Huber - LabCompliance Slide 49 Considerations for Testing Number of samples, lots, batches (2-5) One or more concentrations (1-3) Number of repetitive analysis / sample (4-6) One or more analysts? (1-2) One or more days? (2-5) Equipment from one or more manufacturers? (1 -all) Copyright Ludwig Huber - LabCompliance Slide 50 25

26 Possible Pitfalls Scope of the method not defined equipment Method not fully validated Methods are not robust Resources not well planned Equipment, people, time Analysts not trained Acceptance criteria not well defined Copyright Ludwig Huber - LabCompliance Slide 51 Recommendations for Deviations If the tests don t pass acceptance criteria, identify the source of the problem Develop corrective action plan Provide additional training Use other equipment Update the procedure Repeat the tests If successful, document initial results, corrective actions and final results If not successful, develop alternative procedure Copyright Ludwig Huber - LabCompliance Slide 52 26

27 Method Transfer Report Report items and format to be specified in the study transfer plan Summary of method familiarization results Detailed results of transfer study Description of any deviations and from expected results and how they have been resolved Signatures of individuals responsible for transfer studies Copies of supporting material, e.g., chromatograms and spectra Assessment of the transfer study results Copyright Ludwig Huber - LabCompliance Slide 53 Thank You I would like to thank All attendees for your attention IVT for organization and invitation to the conference Give feedback and choose any two from over 150 documents (value: $138) for free: SOPS and/or Validation examples. GOTO: Check topics and details of 100+ audio/video seminars Audio: Video: Copyright Ludwig Huber - LabCompliance Slide 54 27

28 Laboratory Compliance Package With 30 SOPs and Laboratory Master Plan Primer and Interactive audio seminar on laboratory compliance: requirements and strategies for implementation 30 SOPs for fast implementation Multiple forms, templates and examples for consistent and effective implementation Three gap analyses and master plan 10+ reference papers FDA presentations Analysts, IT and QA learn all about requirements and strategies And get SOPs and examples for easy implementation. More info: Copyright Ludwig Huber - LabCompliance Slide 55 28

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

Analytical Method Validation

Analytical Method Validation Analytical Method Validation A. Es-haghi Ph.D. Dept. of Physico chemistry vaccine and serum research institute a.eshaghi@rvsri.ir http://www.rvsri.ir/ Introduction Test procedures for assessment of the

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

Analytical Method Validation for Assay, Related substances & Dissolution. N A Y A N K S H A T R I 1 8 / 0 1 /

Analytical Method Validation for Assay, Related substances & Dissolution. N A Y A N K S H A T R I 1 8 / 0 1 / Analytical Method Validation for Assay, Related substances & Dissolution. N A Y A N K S H A T R I 1 8 / 0 1 / 2 0 1 3 Definitions The objective of validation of an analytical procedure is to demonstrate

More information

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external

More information

GUIDELINES ON VALIDATION APPENDIX 4 ANALYTICAL METHOD VALIDATION

GUIDELINES ON VALIDATION APPENDIX 4 ANALYTICAL METHOD VALIDATION June 2016 Draft document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 GUIDELINES ON VALIDATION APPENDIX

More information

A Practical Approach to Validation of HPLC Methods Under Current Good Manufacturing Practices

A Practical Approach to Validation of HPLC Methods Under Current Good Manufacturing Practices A Practical Approach to Validation of HPLC Methods Under Current Good Manufacturing Practices Introduction Analytical methods validation is an important regulatory requirement in pharmaceutical analysis.

More information

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:

More information

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to

More information

Analytical Procedures and Methods Validation for Drugs and Biologics

Analytical Procedures and Methods Validation for Drugs and Biologics Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Guideline on Process Validation

Guideline on Process Validation 1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /

More information

Validating Methods using Waters Empower TM 2 Method. Validation. Manager

Validating Methods using Waters Empower TM 2 Method. Validation. Manager Validating Methods using Waters Empower TM 2 Method Validation Manager (MVM) Anders Janesten Nordic Informatics Sales Specialist 2008 Waters Corporation Decision-centric centric method development information

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) NOTE FOR GUIDANCE ON PROCESS VALIDATION

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) NOTE FOR GUIDANCE ON PROCESS VALIDATION The European Agency for the Evaluation of Medicinal Products London, 1 March 2001 CPMP/QWP/848/96 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

More information

Validation and Calibration. Definitions and Terminology

Validation and Calibration. Definitions and Terminology Validation and Calibration Definitions and Terminology ACCEPTANCE CRITERIA: The specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with an

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

Method Validation. Introduction. Página Web 1 de 16

Method Validation. Introduction. Página Web 1 de 16 Página Web 1 de 16 Method Validation Introduction Strategy for Validation of Methods Validation of Standard Methods Revalidation Parameters for Method Validation Selectivity/specificity Precision and Reproducibility

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:

More information

Why System Suitability Tests Are Not a Substitute for Analytical Instrument Qualification

Why System Suitability Tests Are Not a Substitute for Analytical Instrument Qualification White paper System Suitability Tests and AIQ R.D.McDowall PhD Principal, McDowall Consulting Paul Smith European Validation Program Manager, PerkinElmer Nicola Vosloo PhD European Market Development Leader,

More information

Principles of HPLC Validation

Principles of HPLC Validation Principles of HPLC Validation A short course in the systematic validation of HPLC methods Principles of HPLC Validation A short course in the systematic validation of HPLC methods What does it cover? This

More information

Guide for the Bioequivalence -Module 5

Guide for the Bioequivalence -Module 5 Guide for the Bioequivalence -Module 5 Prepared by the Technical Subcommittee s experts under the supervision of Dr. Rita Karam, Head of Quality Assurance of Pharmaceutical Products 1 INTRODUCTION Two

More information

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS. GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

QbD Considerations for Analytical Methods - FDA Perspective

QbD Considerations for Analytical Methods - FDA Perspective QbD Considerations for Analytical Methods - FDA Perspective IFPAC Annual Meeting Baltimore, January 25, 2013 Sharmista Chatterjee, Ph.D. CMC Lead for QbD ONDQA/CDER/FDA Outline Role of analytics in drug

More information

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical

More information

Pharmaceutical Quality Systems: US Perspective

Pharmaceutical Quality Systems: US Perspective Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current

More information

ELEMENTAL IMPURITY ANALYSIS IN REGULATED PHARMACEUTICAL LABORATORIES. A Primer

ELEMENTAL IMPURITY ANALYSIS IN REGULATED PHARMACEUTICAL LABORATORIES. A Primer ELEMENTAL IMPURITY ANALYSIS IN REGULATED PHARMACEUTICAL LABORATORIES A Primer Table of Contents Preface 5 1. Introduction 7 Background 7 Content of the Primer 7 Resources 7 2. Regulations and Compliance

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

USP Guideline for Submission of New Food Ingredient Monographs to the Food Chemicals Codex

USP Guideline for Submission of New Food Ingredient Monographs to the Food Chemicals Codex 1. INTRODUCTION AND PURPOSE The (FCC) is constantly updated and modernized through an open and transparent process. Many proposed updates to the FCC, including new monograph submissions, are submitted

More information

Applying Statistics Recommended by Regulatory Documents

Applying Statistics Recommended by Regulatory Documents Applying Statistics Recommended by Regulatory Documents Steven Walfish President, Statistical Outsourcing Services steven@statisticaloutsourcingservices.com 301-325 325-31293129 About the Speaker Mr. Steven

More information

Change Control. A Key Element of a Quality System

Change Control. A Key Element of a Quality System IVT 9 th Annual Conference Change Control Change Control A Key Element of a Quality System Jerry Lanese Ph.D. CMC The Lanese Group, Inc. 2011 The Lanese Group 1 Will discuss A Quality System What is it

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q4B ANNEX 12

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q4B ANNEX 12 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

Pharmaceutical Industry Trends Approaches to Process Validation and Risk Management (Quality Systems and cgmps)

Pharmaceutical Industry Trends Approaches to Process Validation and Risk Management (Quality Systems and cgmps) Pharmaceutical Industry Trends Approaches to Process Validation and Risk Management (Quality Systems and cgmps) Anita R. Michael, Pharmaceutical Specialist FDA Office of Regulatory Affairs 1 Process Validation

More information

Quantitative work in HPLC

Quantitative work in HPLC Quantitative work in HPLC Dr. Shulamit Levin Medtechnica www.forumsci.co.il/hplc Dr. Shulamit Levin, Medtechnica 1 Quantitative work in HPLC Dr. Shulamit Levin Medtechnica Data Handling Analytical Chemistry

More information

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration & Preventative Maintenance Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration: A comparison of two instruments or measuring devices one of which is a standard of known

More information

Best Practice In A Change Management System

Best Practice In A Change Management System Quality & Compliance Associates, LLC Best Practice In A Change Management System President Quality & Compliance Associates, LLC Change Control and Its Role in a Continuous Improvement Environment 3 Benefits

More information

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical

More information

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management

More information

Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination of Sodium Alginate from Oral Suspension

Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination of Sodium Alginate from Oral Suspension International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.2, No.2, pp 1634-1638, April-June 2010 Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination

More information

Validation and Part 11/Annex 11 Compliance of Computer Systems

Validation and Part 11/Annex 11 Compliance of Computer Systems Validation and Part 11/Annex 11 Compliance of Computer Systems by Dr. Ludwig Huber 05 & 06 June 2013, Elite World Hotels, Istanbul - TURKEY Why to attend Computer systems should be validated to demonstrate

More information

Analytical Methods for Cleaning Validation

Analytical Methods for Cleaning Validation Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2011, 3 (6): 232-239 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4

More information

Analytical Method Validation

Analytical Method Validation 1 Analytical Method Validation Pedro Lopez Garcia 1, Ernesto Buffoni 1, Fabio Pereira Gomes 1 and Jose Luis Vilchez Quero 2 1 Instituto de Aperfeiçoamento Farmacêutico (IAF) 2 Department of Analytical

More information

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5 European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND

More information

Lifecycle Management of Analytical Procedures; What is it all about? Jane Weitzel Independent Consultant

Lifecycle Management of Analytical Procedures; What is it all about? Jane Weitzel Independent Consultant Lifecycle Management of Analytical Procedures; What is it all about? Jane Weitzel Independent Consultant 2 USP Stimuli Article Lifecycle Management of Analytical Procedures: Method Development, Procedure

More information

Overview of Cleaning Validation in Pharmaceutical Industry

Overview of Cleaning Validation in Pharmaceutical Industry Available online at www.ijpqa.com International Journal of Pharmaceutical Quality Assurance 2010; 2(2), 26-30 Review Article ISSN: 0975-9506 Overview of Cleaning Validation in Pharmaceutical Industry Anindya

More information

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON TABLET FRIABILITY GENERAL CHAPTER Q4B ANNEX 9(R1)

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON TABLET FRIABILITY GENERAL CHAPTER Q4B ANNEX 9(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current

More information

Design of Experiments for Analytical Method Development and Validation

Design of Experiments for Analytical Method Development and Validation Design of Experiments for Analytical Method Development and Validation Thomas A. Little Ph.D. 2/12/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com

More information

Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification a

Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification a STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Lifecycle Management of Analytical Procedures: Method Development, Procedure

More information

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs. 15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2

More information

Common Process Related Deficiencies

Common Process Related Deficiencies Common Process Related Deficiencies Sharmista Chatterjee, Ph.D. Division Director (Acting) Division of Process Assessment II Office of Process & Facilities (OPF)/OPQ/CDER/FDA 2016 GPhA CMC Workshop May

More information

Analytical method development

Analytical method development Training workshop: Pharmaceutical development with focus on paediatric formulations Presenter: Birgit Schmauser,, PhD Contact details: Federal Institute for Drugs and Medical Devices (BfArM), Germany Birgit.Schmauser@bfarm.de

More information

2014 Annual Report on Inspections of Establishments

2014 Annual Report on Inspections of Establishments 2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered

More information

Auditing Chromatographic Electronic Data. Jennifer Bravo, M.S. QA Manager Agilux Laboratories

Auditing Chromatographic Electronic Data. Jennifer Bravo, M.S. QA Manager Agilux Laboratories Auditing Chromatographic Electronic Data Jennifer Bravo, M.S. QA Manager Agilux Laboratories Outline Raw data paper or electronic record? Controls for electronic data Auditing electronic records Warning

More information

Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission

Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission 1 2 3 25 April 2014 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided

More information

Deviation and Out of Specification Handling

Deviation and Out of Specification Handling Deviation and Out of Specification Handling APV Training Course GMP Requirements June,10th to11th 2004 Istanbul, Turkey Dr. Jürgen Mählitz GMP Inspector Fronhof 10 D-86152 Augsburg Germany Dr. Jürgen Mählitz

More information

Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate

Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate Cantaurus, Vol. 7, 5-8, May 1999 McPherson College Division of Science and Technology Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate Janet Bowen ABSTRACT Sulfate is used in

More information

Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants

Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality

More information

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where

More information

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)

More information

LIBRARY GUIDE: Pharmaceutical GMPs

LIBRARY GUIDE: Pharmaceutical GMPs LIBRARY GUIDE: Pharmaceutical GMPs Table of Contents Overview............................................................................ 3 Courses Listed by Functional Area....................................................

More information

A Stability Program for the Distribution of Drug Products

A Stability Program for the Distribution of Drug Products A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained

More information

Thermo Scientific Dionex Chromeleon 7 Chromatography Data System Software

Thermo Scientific Dionex Chromeleon 7 Chromatography Data System Software Thermo Scientific Dionex Chromeleon 7 Chromatography Data System Software Frank Tontala, Thermo Fisher Scientific, Germering, Germany Technical Note 708 Key Words Chromeleon Chromatography Data System,

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control

More information

Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation)

Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation) Global CompliancePanel Knowledge, a Way Forward 2-day In-person Seminar: Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation) Los Angeles, CA July 28th & 29th, 2016

More information

Workshop A Design Space (DS)

Workshop A Design Space (DS) Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information

More information

PHARMACEUTICAL REFERENCE STANDARDS

PHARMACEUTICAL REFERENCE STANDARDS PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA

FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA The NFL White Paper Series Volume 7, January 2013 Overview and a Scenario With so

More information

Method Development and Validation for Particle Size and Shape Measurements

Method Development and Validation for Particle Size and Shape Measurements Method Development and Validation for Particle Size and Shape Measurements Ulf Willén Divisional Product Manager Analytical Imaging Systems Malvern Instruments Ltd, Malvern, UK. FDA guidance: when should

More information

ERDOSTEINE - MONOGRAPH.

ERDOSTEINE - MONOGRAPH. STRUCTURAL FORMULA (±1S-(2-[N-3-(2-oxotetrahydro thienyl)]acetamido)-thioglycolic acid) C 8 H 11 NO 4 S 2 M.W. = 249.307 DESCRIPTION Color : White to ivory white Appearance : Microcrystalline powder SOLUBILITY

More information

Laboratory Self-Audits

Laboratory Self-Audits P e e r R e v i e w e d : A u d i t 101 Laboratory Self-Audits Paul L. Pluta and Jerry Lanese Audit 101 provides useful and practical information that addresses various topics associated with audits. Common-sense

More information

Cleaning Validation in the Pharmaceutical Industry

Cleaning Validation in the Pharmaceutical Industry Cleaning Validation in the Pharmaceutical Industry By Mowafak Nassani, Ph.D. INTRODUCTION Cleaning validation in the pharmaceutical industry has been a topic of ever-increasing interest and scrutiny in

More information

Process Validation: Practical Aspects of the New FDA Guidance

Process Validation: Practical Aspects of the New FDA Guidance Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory

More information

A VALIDATED RP-HPLC METHOD FOR ESTIMATION OF REGORAFENIB IN BULK AND TABLET DOSAGE FORM

A VALIDATED RP-HPLC METHOD FOR ESTIMATION OF REGORAFENIB IN BULK AND TABLET DOSAGE FORM A VALIDATED RP-HPLC METHOD FOR ESTIMATION OF REGORAFENIB IN BULK AND TABLET DOSAGE FORM ABSTRACT A simple, selective, linear and accurate isocratic RP-HPLC method has been developed for the estimation

More information

White paper: FDA Guidance for Industry Update Process Validation

White paper: FDA Guidance for Industry Update Process Validation White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,

More information

Regulatory Updates Including Method Validation, Convergence of GAMP & USP <1058>, Data Integrity & Paper versus Electronic Raw Data

Regulatory Updates Including Method Validation, Convergence of GAMP & USP <1058>, Data Integrity & Paper versus Electronic Raw Data Regulatory Updates Including Method Validation, Convergence of GAMP & USP , Data Integrity & Paper versus Electronic Raw Data Bob McDowall McDowall Consulting McDowall Consulting 2014 www.rdmcdowall.com

More information

Analytical Test Method Validation Report Template

Analytical Test Method Validation Report Template Analytical Test Method Validation Report Template 1. Purpose The purpose of this Validation Summary Report is to summarize the finding of the validation of test method Determination of, following Validation

More information

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory

More information

Ecology Quality Assurance Glossary

Ecology Quality Assurance Glossary Ecology Quality Assurance Glossary Edited by William Kammin, Ecology Quality Assurance Officer Accreditation - A certification process for laboratories, designed to evaluate and document a lab s ability

More information

State of Control Over the Lifecycle and Process Validation (New and Legacy Products)

State of Control Over the Lifecycle and Process Validation (New and Legacy Products) State of Control Over the Lifecycle and Process Validation (New and Legacy Products) Grace McNally Branch Chief (acting), Regulatory Policy and Collaboration Branch FDA/CDER/Office of Compliance ICH Q10,

More information

The Future of Process Validation - Going Back to Basics

The Future of Process Validation - Going Back to Basics IVTJVT1107.qxd 10/8/07 3:27 PM Page 36 The Future of Process Validation - Going Back to Basics The New FDA Perspective as a Refocus on the Original Definition of Process Validation BY MIGUEL MONTALVO INTRODUCTION

More information

Blood, Plasma, and Cellular Blood Components INTRODUCTION

Blood, Plasma, and Cellular Blood Components INTRODUCTION Blood, Plasma, and Cellular Blood Components INTRODUCTION This chapter of the Guideline provides recommendations to Sponsors of Requests for Revision for new monographs for blood, plasma, and cellular

More information

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases

More information

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION

IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION IN VITRO BINDING BIOEQUIVALENCE STUDY SUMMARY TABLES AND SAS TRANSPORT FORMATTED TABLES FOR DATASET SUBMISSION I. For Calcium Acetate Drug Products Table I.1 Submission Summary * Drug Product Name Strength(s)

More information

Method Validation. Ross Molinaro, PhD, MT(ASCP), DABCC, FACB Emory University Atlanta, GA

Method Validation. Ross Molinaro, PhD, MT(ASCP), DABCC, FACB Emory University Atlanta, GA Method Validation Ross Molinaro, PhD, MT(ASCP), DABCC, FACB Emory University Atlanta, GA Learning Objectives After this presentation, you should be able to: 1. Define method evaluation. 2. List the steps

More information

[Research article] RP-HPLC Assay Method Validation for the estimation of new Antiretroviral drug Lamivudine in Bulk and Tablet dosage form

[Research article] RP-HPLC Assay Method Validation for the estimation of new Antiretroviral drug Lamivudine in Bulk and Tablet dosage form 12 IJPAR Volume 1 Issue 1 Dec_ 2012 Available Online at: www.ijpar.com [Research article] RP-HPLC Assay Method Validation for the estimation of new Antiretroviral drug in Bulk and Tablet dosage form *

More information

Issues Related to PET Radiopharmaceutical Monographs & General Chapters

Issues Related to PET Radiopharmaceutical Monographs & General Chapters Issues Related to PET Radiopharmaceutical Monographs & General Chapters Steve Zigler, Ph.D. PETNET Solutions, Inc. Member, USP Expert Committee on Radiopharmaceuticals and Medical Imaging Agents (RMI)

More information

Quality by Design Trevor Schoerie

Quality by Design Trevor Schoerie Quality by Design Trevor Schoerie Guidelines Please contribute and ask questions Please relax and enjoy yourself Phone on silent / mute? Native presentation can be emailed. Slide 2 Agenda The what, who,

More information

Harmonizing Change Control Processes Globally

Harmonizing Change Control Processes Globally Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses

More information

OOS Results in FDA Warning Letters How to Perform Appropriate Investigation, and a Touch of CAPA plus Case Studies

OOS Results in FDA Warning Letters How to Perform Appropriate Investigation, and a Touch of CAPA plus Case Studies OOS Results in FDA Warning Letters How to Perform Appropriate Investigation, and a Touch of CAPA plus Case Studies Abbass Kamalizad, Ph.D. President, ACPC Group kamalizad@acpcgroup.com Presented to SCPDG,

More information

Preparing for an FDA Pre-Approval Inspection (PAI)

Preparing for an FDA Pre-Approval Inspection (PAI) Preparing for an FDA Pre-Approval Inspection (PAI) Jorge Torres CMQ/OE, CQE, CQA July, 2007 1 Agenda Introduction Understanding the PAI Experience: What to Expect Inspection Management Plan Preparing for

More information

Considerations for veterinary scientific advice and marketing authorisations

Considerations for veterinary scientific advice and marketing authorisations Considerations for veterinary scientific advice and marketing authorisations Presented by: Mary O Grady Irish Medicines Board An agency of the European Union Veterinary scientific advice Veterinary marketing

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

STRUCTURE OF CHEMICAL COMPOUNDS, METHODS OF ANALYSIS AND PROCESS CONTROL

STRUCTURE OF CHEMICAL COMPOUNDS, METHODS OF ANALYSIS AND PROCESS CONTROL Pharmaceutical Chemistry Journal Vol. 38, No. 4, 004 STRUCTURE OF CHEMICAL COMPOUNDS, METHODS OF ANALYSIS AND PROCESS CONTROL VALIDATION OF HPLC TECHNIQUES FOR PHARMACEUTICAL ANALYSIS N. A. Épshtein 1

More information

FDA Guidance for Industry Update - Process Validation

FDA Guidance for Industry Update - Process Validation FDA Guidance Update: Process Validation: General Principles and Practices White Paper FDA Guidance for Industry Update - Process Validation The changing face of Validation; are IQ, OQ and PQ really dead

More information

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information